Moleculin Biotech Inc (MBRX) - Total Liabilities
Based on the latest financial reports, Moleculin Biotech Inc (MBRX) has total liabilities worth $7.12 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Moleculin Biotech Inc - Total Liabilities Trend (2015–2025)
This chart illustrates how Moleculin Biotech Inc's total liabilities have evolved over time, based on quarterly financial data. See MBRX working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Moleculin Biotech Inc Competitors by Total Liabilities
The table below lists competitors of Moleculin Biotech Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Guardforce AI Co Ltd
NASDAQ:GFAI
|
USA | $14.99 Million |
|
Skin Elements Ltd
AU:SKN
|
Australia | AU$429.34K |
|
Trust Finance Indonesia Tbk
JK:TRUS
|
Indonesia | Rp33.40 Billion |
|
Prochem S.A.
WAR:PRM
|
Poland | zł90.55 Million |
|
Nuvotec
KQ:060260
|
Korea | ₩32.17 Billion |
|
Huadi International Group Co Ltd
NASDAQ:HUDI
|
USA | $32.59 Million |
|
Wegmans Holdings Berhad
KLSE:0197
|
Malaysia | RM46.45 Million |
|
Mico BioMed Co. Ltd.
KQ:214610
|
Korea | ₩7.88 Billion |
Liability Composition Analysis (2015–2025)
This chart breaks down Moleculin Biotech Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Moleculin Biotech Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Moleculin Biotech Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Moleculin Biotech Inc (2015–2025)
The table below shows the annual total liabilities of Moleculin Biotech Inc from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $7.12 Million | -34.95% |
| 2024-12-31 | $10.95 Million | -9.86% |
| 2023-12-31 | $12.14 Million | +132.15% |
| 2022-12-31 | $5.23 Million | +2.63% |
| 2021-12-31 | $5.10 Million | -54.78% |
| 2020-12-31 | $11.27 Million | +16.63% |
| 2019-12-31 | $9.66 Million | +81.89% |
| 2018-12-31 | $5.31 Million | +124.65% |
| 2017-12-31 | $2.37 Million | +65.09% |
| 2016-12-31 | $1.43 Million | +85.38% |
| 2015-12-31 | $772.79K | -- |
About Moleculin Biotech Inc
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 po… Read more